Alpha-CGRP
Evidence: CCardiovascular / Vascular
Evidence Snapshot
Regulatory Context
This page summarizes research on the peptide and does not imply that the peptide is an FDA-approved drug or approved for a particular indication. Molecule-specific regulatory status requires verification against official regulatory records.
Research Takeaway
Alpha-CGRP is the CALCA-derived mature CGRP isoform and must be distinguished from Beta-CGRP/CALCB-derived CGRP, calcitonin, amylin, adrenomedullin, and CGRP-pathway drugs.
Evidence boundary: Generic "CGRP" sources require exact isoform adjudication before they can support this page.
See all 7 evidence claims →Quick Summary
Alpha-CGRP is the CALCA-derived CGRP isoform and a powerful human vasoactive neuropeptide. Direct infusion studies provide strong evidence for acute vascular and migraine-provocation pharmacology, but pathway-antagonist success does not make Alpha-CGRP itself a therapeutic agent, and the limited Raynaud evidence is too small to establish treatment efficacy.
Mechanism & Research Overview
Alpha-CGRP is the CALCA-derived CGRP isoform and a powerful human vasoactive neuropeptide. Direct infusion studies provide strong evidence for acute vascular and migraine-provocation pharmacology, but pathway-antagonist success does not make Alpha-CGRP itself a therapeutic agent, and the limited Raynaud evidence is too small to establish treatment efficacy.
Evidence Claims
Individual scientific statements drawn from the sources cited below, each shown with the specific evidence boundary that statement does not establish.
Supported
Alpha-CGRP is the CALCA-derived mature CGRP isoform and must be distinguished from Beta-CGRP/CALCB-derived CGRP, calcitonin, amylin, adrenomedullin, and CGRP-pathway drugs.
Does not establish
Evidence boundary: Generic "CGRP" sources require exact isoform adjudication before they can support this page.
Sources: BIBN4096BS antagonizes human alpha-calcitonin gene related peptide-induced headache and extracerebral artery dilatation; Involvement of calcitonin gene-related peptide in migraine: regional cerebral blood flow and blood flow velocity in migraine patients
Supported
Human Alpha-CGRP has been directly infused in controlled studies and produces potent vascular and systemic hemodynamic effects.
Does not establish
Evidence boundary: These experiments primarily characterize pharmacology/provocation rather than therapeutic benefit.
Sources: A comparison of the effects of human alpha calcitonin gene-related peptide and glyceryl trinitrate on regional blood velocity in man; BIBN4096BS antagonizes human alpha-calcitonin gene related peptide-induced headache and extracerebral artery dilatation; Involvement of calcitonin gene-related peptide in migraine: regional cerebral blood flow and blood flow velocity in migraine patients; Dilation by CGRP of middle meningeal artery and reversal by sumatriptan in normal volunteers
Supported
In migraine-related human studies, Alpha-CGRP infusion can provoke headache and cranial vascular changes.
Does not establish
Evidence boundary: Provoking migraine-like physiology is not evidence that Alpha-CGRP administration is a treatment.
Sources: BIBN4096BS antagonizes human alpha-calcitonin gene related peptide-induced headache and extracerebral artery dilatation; Involvement of calcitonin gene-related peptide in migraine: regional cerebral blood flow and blood flow velocity in migraine patients; Dilation by CGRP of middle meningeal artery and reversal by sumatriptan in normal volunteers
Supported
A very small randomized crossover study in Raynaud's disease reported improved hand blood-flow/rewarming measures after human Alpha-CGRP infusion.
Does not establish
Evidence boundary: Six patients and surrogate vascular outcomes are far too limited to establish Alpha-CGRP as an effective or standard Raynaud treatment.
Supported
Clinical efficacy of gepants, anti-CGRP antibodies, anti-CGRP-receptor antibodies, sumatriptan, or other pathway-targeting drugs cannot be transferred to therapeutic efficacy of administering Alpha-CGRP itself.
Sources: BIBN4096BS antagonizes human alpha-calcitonin gene related peptide-induced headache and extracerebral artery dilatation; Dilation by CGRP of middle meningeal artery and reversal by sumatriptan in normal volunteers
Supported
Direct Alpha-CGRP infusion studies demonstrate acute headache, flushing/vasodilation, tachycardia, and blood-pressure effects as relevant human pharmacology/safety signals.
Does not establish
Evidence boundary: Acute provocation studies do not define long-term safety.
Sources: A comparison of the effects of human alpha calcitonin gene-related peptide and glyceryl trinitrate on regional blood velocity in man; BIBN4096BS antagonizes human alpha-calcitonin gene related peptide-induced headache and extracerebral artery dilatation; Involvement of calcitonin gene-related peptide in migraine: regional cerebral blood flow and blood flow velocity in migraine patients; Dilation by CGRP of middle meningeal artery and reversal by sumatriptan in normal volunteers
Supported
No molecule-specific regulatory conclusion is frozen for native Alpha-CGRP in Stage 2A.
Safety & Evidence Limitations
Considerations reported in the sources cited on this page — not a complete list of every possible risk, and not medical advice.
Safety Consideration
Headache/migraine provocation is directly demonstrated in human Alpha-CGRP studies.Safety Consideration
Vasodilation, flushing, tachycardia, and arterial-pressure changes occur during experimental infusion.Safety Consideration
Long-term systemic safety is not established by short provocation/vascular studies.
Research Areas Being Studied
Research areas discussed on this page reflect the Cardiovascular / Vascular category and the sources cited below.
Findings Reported in Studies
Educational summary only — reported in cited studies, not a claim of proven benefit.
- Dilation by CGRP of middle meningeal artery and reversal by sumatriptan in normal volunteers (2010):
- Involvement of calcitonin gene-related peptide in migraine: regional cerebral blood flow and blood flow velocity in migraine patients (2008):
- BIBN4096BS antagonizes human alpha-calcitonin gene related peptide-induced headache and extracerebral artery dilatation (2005):
- Prolonged effect of CGRP in Raynaud's patients: a double-blind randomised comparison with prostacyclin (1991):
- The effect of calcitonin gene-related peptide (CGRP) on human forearm blood flow (1990):
- A comparison of the effects of human alpha calcitonin gene-related peptide and glyceryl trinitrate on regional blood velocity in man (1989):
Study Tables by Evidence Type
Human Studies & Clinical Data
| Title | Year | Population / Model | Dose / Duration / Finding | Safety Notes | Source |
|---|---|---|---|---|---|
| Dilation by CGRP of middle meningeal artery and reversal by sumatriptan in normal volunteers | 2010 | 18 healthy volunteers; double-blind randomized placebo-controlled crossover | Human Alpha-CGRP dilated the middle meningeal artery and induced headache-related physiology; sumatriptan reversed meningeal dilation. | ||
| Involvement of calcitonin gene-related peptide in migraine: regional cerebral blood flow and blood flow velocity in migraine patients | 2008 | 12 migraine-without-aura patients; double-blind crossover | IV human Alpha-CGRP altered cerebral blood-flow velocity and systemic hemodynamics and served as a migraine-provocation/pathophysiology probe. | ||
| BIBN4096BS antagonizes human alpha-calcitonin gene related peptide-induced headache and extracerebral artery dilatation | 2005 | Ten healthy volunteers; double-blind placebo-controlled crossover | Alpha-CGRP infusion provoked headache and extracerebral vascular dilation; CGRP-receptor antagonism blocked these effects. | ||
| Prolonged effect of CGRP in Raynaud's patients: a double-blind randomised comparison with prostacyclin | 1991 | Six patients with Raynaud's disease; randomized double-blind crossover | Human Alpha-CGRP increased hand skin blood flow and improved thermographic rewarming after infusion compared with prostacyclin under the protocol. | ||
| The effect of calcitonin gene-related peptide (CGRP) on human forearm blood flow | 1990 | Humans; intra-arterial and systemic CGRP infusion | CGRP produced dose-dependent forearm/cutaneous vasodilation and systemic hemodynamic effects. | ||
| A comparison of the effects of human alpha calcitonin gene-related peptide and glyceryl trinitrate on regional blood velocity in man | 1989 | Ten normal volunteers | IV human Alpha-CGRP produced prominent tachycardia and regional vascular effects with little/no blood-pressure fall at the studied infusion target. |
Animal / Cell / Preclinical Data
No Animal / Cell / Preclinical Data Listed Yet
This section will be updated as sources are added.
Regulatory Documents & Official Trial Registries
No Regulatory Documents & Official Trial Registries Listed Yet
This section will be updated as sources are added.
Anecdotal Reported Patterns — Not Medical Advice
Anecdotal Reported Patterns — Not Medical Advice
Reported dosing patterns are included for educational context only. They are self-reported, unverified, not medical advice, and not instructions for human use. Community-submitted patterns are not yet available in this Phase 1 prototype; this section is a placeholder reserved for moderated, aggregated community data.
Lab Markers to Discuss With a Clinician
Educational topics only — not self-monitoring instructions.
FAQ
Disclaimer
Educational information only. This page summarizes published and official research and does not provide medical advice, a recommendation, or instructions for human use.
Educational use only. This content is provided for informational and research-summary purposes only. It is not medical advice, not a treatment recommendation, not a dosing guide, and not a substitute for care from a licensed medical professional. Nothing here is intended to diagnose, treat, cure, prevent, or mitigate disease. Reported dosing patterns, when shown elsewhere on the site, must be labeled either as Study / Trial Dosing or Anecdotal Reported Patterns — Not Medical Advice. Community reports are self-reported, unverified, and not scientific proof.
Community-reported experiences, once enabled, must be displayed only as moderated, anonymized, or aggregated data. They are anecdotal, self-reported, unverified, and should never be presented as proof of safety, efficacy, or expected results.
Content status: Published. Last updated 2026-08-25.
Follow research updates for Alpha-CGRP
Get notified in your MitoCore account when this profile is updated, a new study is added, or its evidence grade changes.
Get updates when new studies or safety notes are added for this peptide.
Get educational updates on new studies, evidence-grade changes, and safety notes. Educational content only — not medical advice.